MA50552A - Dérivés de liaison à l'albumine sensibles au glucose - Google Patents

Dérivés de liaison à l'albumine sensibles au glucose

Info

Publication number
MA50552A
MA50552A MA050552A MA50552A MA50552A MA 50552 A MA50552 A MA 50552A MA 050552 A MA050552 A MA 050552A MA 50552 A MA50552 A MA 50552A MA 50552 A MA50552 A MA 50552A
Authority
MA
Morocco
Prior art keywords
albumin binding
glucose sensitive
binding derivatives
sensitive albumin
derivatives
Prior art date
Application number
MA050552A
Other languages
English (en)
French (fr)
Inventor
Vojtech Balsánek
Carsten Behrens
Zuzana Drobnáková
Ladislav Droz
Mikael Kofoed Hansen
Miroslav Havránek
Thomas Hoeg-Jensen
Vladislav Kotek
Thomas Kruse
Martin Werner Borchsenius Münzel
Jakob Ewald Rasmussen
Per Sauerberg
Ivan Snajdr
Milan Stengl
Henning Thøgersen
Hana Vánová
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA50552A publication Critical patent/MA50552A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q3/00Condition responsive control processes
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/10Methods of screening libraries by measuring physical properties, e.g. mass
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G01N24/088Assessment or manipulation of a chemical or biochemical reaction, e.g. verification whether a chemical reaction occurred or whether a ligand binds to a receptor in drug screening or assessing reaction kinetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827Total protein determination, e.g. albumin in urine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA050552A 2017-11-09 2018-11-08 Dérivés de liaison à l'albumine sensibles au glucose MA50552A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17200734 2017-11-09
EP18178294 2018-06-18

Publications (1)

Publication Number Publication Date
MA50552A true MA50552A (fr) 2020-09-16

Family

ID=64049277

Family Applications (2)

Application Number Title Priority Date Filing Date
MA050552A MA50552A (fr) 2017-11-09 2018-11-08 Dérivés de liaison à l'albumine sensibles au glucose
MA71363A MA71363A (fr) 2017-11-09 2018-11-08 L'acide 1-hydroxy-4-(trifluorométhyl)-1,3-dihydrobenzo[c] [1,2]oxaborole-6-carboxylique et son utilisation dans la synthèse de dérivés de liaison à l'albumine sensibles au glucose

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA71363A MA71363A (fr) 2017-11-09 2018-11-08 L'acide 1-hydroxy-4-(trifluorométhyl)-1,3-dihydrobenzo[c] [1,2]oxaborole-6-carboxylique et son utilisation dans la synthèse de dérivés de liaison à l'albumine sensibles au glucose

Country Status (7)

Country Link
US (4) US11186595B2 (enExample)
EP (2) EP3707145B1 (enExample)
JP (3) JP7254792B2 (enExample)
CN (2) CN111315751B (enExample)
ES (1) ES2956032T3 (enExample)
MA (2) MA50552A (enExample)
WO (1) WO2019092125A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3291828A4 (en) 2015-05-06 2018-10-03 Alborz Mahdavi Glucose responsive insulins
CN111315751B (zh) * 2017-11-09 2023-12-12 诺和诺德股份有限公司 葡萄糖敏感性白蛋白结合衍生物
TW202112397A (zh) * 2019-03-29 2021-04-01 丹麥商諾佛.儂迪克股份有限公司 葡萄糖敏感型胰島素衍生物
CN112174989B (zh) * 2019-07-02 2023-06-20 江西同和药业股份有限公司 一种克立硼罗的制备方法
JP2022543586A (ja) * 2019-07-31 2022-10-13 サーマリン インコーポレイテッド グルコース調節型立体配座スイッチを有するインスリン類似体
MX2022012208A (es) * 2020-03-31 2022-12-15 Protomer Tech Inc Conjugados para reactividad selectiva a dioles vecinales.
US20240374735A1 (en) * 2020-11-19 2024-11-14 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
EP4255468A4 (en) * 2020-12-02 2024-06-05 The Regents of University of California Injectable biodegradable polymeric complex for glucose-responsive insulin delivery
WO2022235691A1 (en) * 2021-05-03 2022-11-10 The Trustees Of Indiana University Molecular design of glucose sensors in glucose-responsive insulin analogues
CN114478597B (zh) * 2021-12-29 2023-08-29 宁波大学 一种快速识别葡萄糖手性的试剂及其制备方法和应用
US12139502B2 (en) 2022-05-18 2024-11-12 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
KR20250165660A (ko) * 2023-04-11 2025-11-26 프로토머 테크놀로지스 인크. 1개 이상의 디보로네이트를 함유하는 화합물 및 관련 인슐린 유사체
KR20250015926A (ko) 2023-07-18 2025-02-03 노보 노르디스크 에이/에스 인슐린 유도체의 약학적 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930001305B1 (ko) 1989-10-19 1993-02-25 니뽕 유우시 가부시끼가이샤 당 응답형 고분자 복합체(Polymer Complexes of Sugar Response Type)
US7316999B2 (en) * 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
EP1290024A1 (en) * 2000-06-02 2003-03-12 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
AU2002349295A1 (en) 2001-12-02 2003-06-17 Novo Nordisk A/S Glucose dependant release of insulin from glucose sensing insulin derivatives
US7317000B2 (en) 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
WO2003105860A1 (en) 2002-06-14 2003-12-24 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
DE102008052314A1 (de) * 2008-10-15 2010-04-22 Syntatec Chemicals Gmbh Aromatische und heteroaromatische Poly-trifluoroborate und Verfahren zur Herstellung
ES2611040T3 (es) 2009-06-30 2017-05-04 Novo Nordisk A/S Derivados de insulina
TWI458732B (zh) * 2012-06-27 2014-11-01 Univ Nat Chiao Tung 具硼酸基團連接子及含有其之生物感測元件
US9867869B2 (en) 2012-12-12 2018-01-16 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
WO2015097276A1 (en) * 2013-12-23 2015-07-02 Syngenta Participations Ag Benzoxaborole fungicides
WO2015106292A1 (en) * 2014-01-13 2015-07-16 Coferon, Inc. Bcr-abl tyrosine-kinase ligands capable of dimerizing in an aqueous solution, and methods of using same
AR103397A1 (es) * 2015-01-13 2017-05-10 Syngenta Participations Ag Oxoborazoles microbicidas
EP3270949B1 (en) 2015-03-13 2025-01-29 Case Western Reserve University Insulin analogues containing a glucose-regulated conformational switch
EP3291828A4 (en) 2015-05-06 2018-10-03 Alborz Mahdavi Glucose responsive insulins
UA121354C2 (uk) * 2016-05-12 2020-05-12 Анакор Фармасутікалз, Інк. Нові сполуки для лікування паразитарних захворювань
US10690675B2 (en) * 2017-04-14 2020-06-23 Georgia Tech Research Corporation Methods for enriching glycopeptides for global analysis of glycoproteins
CN111315751B (zh) 2017-11-09 2023-12-12 诺和诺德股份有限公司 葡萄糖敏感性白蛋白结合衍生物
EP3781147A4 (en) 2018-04-16 2022-04-20 University of Utah Research Foundation Glucose-responsive insulin

Also Published As

Publication number Publication date
US11767332B2 (en) 2023-09-26
EP3707145A1 (en) 2020-09-16
US11186595B2 (en) 2021-11-30
CN111315751B (zh) 2023-12-12
MA71363A (fr) 2025-04-30
EP4227313A1 (en) 2023-08-16
EP4227313B1 (en) 2025-10-22
JP2025061325A (ja) 2025-04-10
CN111315751A (zh) 2020-06-19
JP7622123B2 (ja) 2025-01-27
US12227528B2 (en) 2025-02-18
JP7254792B2 (ja) 2023-04-10
EP3707145C0 (en) 2023-06-21
EP4227313C0 (en) 2025-10-22
US20230331745A1 (en) 2023-10-19
US20200325160A1 (en) 2020-10-15
EP3707145B1 (en) 2023-06-21
US20220081451A1 (en) 2022-03-17
ES2956032T3 (es) 2023-12-12
JP2021502372A (ja) 2021-01-28
US20250122226A1 (en) 2025-04-17
JP2023080126A (ja) 2023-06-08
WO2019092125A1 (en) 2019-05-16
CN117624207A (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
MA50552A (fr) Dérivés de liaison à l'albumine sensibles au glucose
EP3655432A4 (en) BINDING PROTEINS 1
EP3470430A4 (en) ANTIBODIES FOR BINDING TO THE INTERLEUKIN-4 RECEPTOR
EP3645014A4 (en) Time release sleep aid system
EP3691549A4 (en) BLOOD STOPPER OR RESTRICTION CUFF
LT3571224T (lt) Patobulintos serumo albumino rišamosios medžiagos
EP3690038A4 (en) ANTIBODY PYRROLOBENZODIACEPINE DERIVATIVE CONJUGATE
MA49270A (fr) Récepteurs de liaison à l'antigène améliorés
EP3641762A4 (en) N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
MA53094A (fr) Protéine de liaison à l'antigène anti-steap1
EP3779306A4 (en) FLAVOR RELEASE SYSTEM
EP3749358A4 (en) POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE COMPOSITION
EP3717505A4 (en) GENENICALLY MODIFIED DNA-BINDING PROTEINS
EP3608188A4 (en) PARKING AID
MA54521A (fr) Dérivés d'oxopyridine substitués
EP3708667A4 (en) IMMUNOGLOBULIN BINDING PROTEINS
EP3517091A4 (en) MOTION AID DEVICE
LT3348317T (lt) Žaislas, paeiliui atskleidžiantis vaikui staigmenas
EP3681518A4 (en) CANINE BLOOD PLATES PREPARATIONS
MA43049A (fr) Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1)
EP3853208C0 (fr) Médicament-conjugué comprenant des dérivés de quinoline
EP3445786C0 (en) DIAGNOSIS OF IMMUNE ACTIVATION WITH CLEVER-1, TNF-ALPHA AND HLA-DR BINDERS
EP3688185A4 (en) TEST FOR DIGITAL AFFINITY LINK
EP3617198C0 (en) Guanidine derivative
EP3488121A4 (en) POSITIONAL DAMPER SUPPORT SYSTEM